[ Back to EurekAlert! ]

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute

Rameen Beroukhim, M.D., Ph.D., Dana-Farber Cancer Institute

Caption: Rameen Beroukhim, M.D., Ph.D., and his colleagues at Dana-Farber Cancer Institute and Broad Institute scientists report that large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of meningiomas. Experimental drugs that inhibit these mutant gene pathways are in clinical trials and have shown promising activity, suggesting that targeted therapies already in development or use may work against these specific meningiomas.

Credit: Sam Ogden

Usage Restrictions: None

Related news release: Genomic sequencing identifies mutant 'drivers' of common brain tumor


[ Back to EurekAlert! ]